Emotion has been conceptualized as a dimensional construct, while the number of dimensions - two or three - has been debated. Research has consistently identified two dimensions - valence and arousal - though ample evidence exists that three dimensions are necessary to describe emotion. One proposed third dimension, identified as dominance, is relevant in clinical syndromes, personality and consumer psychology. Dominance refers to an individual's sense of having an ability to affect the environment. Neuroimaging studies have generally focused on the two dimensions of valence and arousal, leaving the neural correlates of dominance unexplored. The current study used functional magnetic resonance imaging to explore the neural basis of dominance in 17 healthy male controls. Participants viewed images from the International Affective Picture System that were selected to represent high and low dominance conditions. Results indicated activation in paralimbic regions, including the bilateral anterior insula for high dominance and the right precuneus for low. The findings of this exploratory study support the consideration of dominance in dimensional models of emotion and suggest that further research is needed to understand the neural representation of dominance in emotional experience.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pscychresns.2013.11.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Department of Neurology and Neurological Sciences Stanford University School of Medicine, Stanford, CA, USA.
Dementia patients often received one clinical diagnosis, yet most of these cases present multiple underlying pathologies. Bringing the transition from clinical-based to biological-based diagnosis holds promise with the diagnostic criteria proposed by the Alzheimer's Association (AA) Revised Criteria for Diagnosis and Staging of Alzheimer's Disease and the Neuronal Synuclein Disease Integrated Staging System (NSD-ISS). This session aims to explore the practical implications of the AA revised criteria for diagnosing and designing clinical trials in Lewy body disease (LBD).
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Indiana University School of Medicine, Department of Psychiatry, Indianapolis, IN, USA.
Background: Major contributors to AD pathogenesis include aggregates of amyloid-β (Aβ) peptides, hyperphosphorylated tau protein, and neuroinflammation. No currently approved treatment stops or significantly slows the progression of AD. Nevertheless, one class of agents that has shown promise is metal chelators.
View Article and Find Full Text PDFGamma-secretases play a pivotal role in the generation of Aβ peptides. Mutations in these enzymes that cause early-onset, autosomal dominant AD shift Aβ production towards generation of longer peptides. We have recently shown that the mutation-induced shifts in the ratio of short-to-long Aβ peptides not only inform about mutation pathogenicity but also allow experimental prediction of the age at dementia onset.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases e.V. (DZNE), Site Rostock/Greifswald, Greifswald, Germany.
Background: Previous trials reported that collaborative Dementia Care Management (cDCM) could be effective for patients and caregivers and cost-effective for healthcare systems in the short term. However, long-term evidence is lacking. Therefore, the study's objective was to determine the long-term efficacy and cost-effectiveness of cDCM compared with usual care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!